INOVIO's DNA-Encoded Antibody Platform Achieves 72-Week Sustained Expression in Phase 1 Trial
核心洞察
INOVIO's Phase 1 trial demonstrated that DNA-encoded monoclonal antibodies (DMAbs) achieved sustained expression in all 39 participants through 72 weeks of follow-up, with peak serum concentrations reaching 1.61 μg/mL.
The synthetic DNA technology enabled in vivo production of monoclonal antibodies directly from muscle cells using intramuscular injection and electroporation delivery, avoiding viral vectors and lipid nanoparticles.
No anti-drug antibodies were detected in approximately 1,000 blood samples, addressing a key limitation of other gene-based delivery platforms while maintaining excellent safety profile.
INOVIO has achieved a significant milestone in DNA-based therapeutics with the publication of Phase 1 trial results in Nature Medicine, demonstrating sustained in vivo production of monoclonal antibodies for 72 weeks. The proof-of-concept study represents a potential paradigm shift in antibody delivery, offering a durable and scalable alternative to traditional monoclonal antibody administration.
Trial Design and Methodology
The open-label, single-center, dose-escalation trial enrolled participants from May 2022 through March 2024, evaluating DNA-encoded monoclonal antibodies (DMAbs) for COVID-19 (搜索). Participants received intramuscular injections of synthetic DNA plasmids encoding AZD5396 and AZD8076, derived from AstraZeneca's cilgavimab and tixagevimab antibodies.
The delivery utilized INOVIO's proprietary CELLECTRA 2000 electroporation device, which temporarily increases cell permeability to facilitate efficient DNA uptake and enable sustained antibody production directly from muscle cells. This approach eliminates the need for chemical adjuvants, lipid nanoparticles, or viral vectors.
Efficacy and Pharmacokinetics
DMAbs were successfully detected in 100% of evaluable participants (n=39), with serum concentrations reaching a peak of 1.61 μg/mL. All participants maintained biologically relevant antibody levels throughout the entire 72-week follow-up period, confirming the durability of the platform's expression capability.
Functional analysis demonstrated that the expressed antibodies retained therapeutic activity, successfully binding to the SARS-CoV-2 spike protein (搜索) and neutralizing pseudovirus in all tested participants. This confirms that the in vivo-produced antibodies maintain the same therapeutic properties as their traditionally manufactured counterparts.
Safety Profile and Immunogenicity
The treatment demonstrated an excellent safety profile, with the most common adverse events being temporary local injection site reactions, including pain and erythema. Three serious adverse events occurred during the study, but all were determined to be unrelated to the investigational product.
Critically, no anti-drug antibodies (ADA) were detected across approximately 1,000 blood samples analyzed throughout the study period. This finding addresses a significant limitation observed with other gene-based delivery platforms, particularly adeno-associated viral vectors, which often trigger immune responses against the delivery system itself.
Platform Technology
INOVIO's DNA medicines platform combines two innovative components: precisely designed DNA plasmids and the proprietary CELLECTRA delivery system. The DNA plasmids function as cellular software, instructing the body's cells to produce specific therapeutic proteins to target and fight disease.
The CELLECTRA delivery devices are designed to optimize DNA medicine delivery without requiring the additional components typically needed by competing platforms. This streamlined approach potentially offers advantages in manufacturing scalability and cost-effectiveness compared to traditional monoclonal antibody production methods.
Clinical Implications
The sustained 72-week expression represents a significant advancement over conventional monoclonal antibody therapies, which typically require frequent dosing due to natural antibody degradation. The ability to achieve long-term therapeutic antibody levels through a single administration could transform treatment paradigms across multiple therapeutic areas.
The research was conducted through collaboration between The Wistar Institute, INOVIO, AstraZeneca, and the Perelman School of Medicine at the University of Pennsylvania, with funding support from the Defense Advanced Research Projects Agency and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.